Medicare Rx Plan Negotiations Will Avert Drug Industry “Windfall” – PhRMA
Executive Summary
The Pharmaceutical Research & Manufacturers of America disagrees with the prediction that Medicare's assumption of "dual eligibles" will be a financial boon for drug makers